<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04666129</url>
  </required_header>
  <id_info>
    <org_study_id>MVT-601-049</org_study_id>
    <nct_id>NCT04666129</nct_id>
  </id_info>
  <brief_title>Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>A Phase 1, Three-Part, Open-Label, Parallel-Cohort Safety and Tolerability Study of Relugolix in Combination With Abiraterone Acetate Plus a Corticosteroid, Apalutamide, or Docetaxel With or Without Prednisone in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myovant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Myovant Sciences GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to assess the safety and tolerability of relugolix with other&#xD;
      agents approved for use in combination with androgen deprivation therapy (ADT) for a 12-week&#xD;
      treatment period and an additional 40-week safety extension period in men with prostate&#xD;
      cancer, either metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic or&#xD;
      metastatic castration-resistant prostate cancer (nmCRPC or mCRPC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a three-part, open-label, parallel-cohort study to assess the safety and tolerability&#xD;
      of relugolix as the ADT component in combination treatment with abiraterone acetate plus a&#xD;
      corticosteroid in patients with mCSPC or mCRPC (Part 1), apalutamide in patients with mCSPC&#xD;
      or nmCRPC (Part 2), or docetaxel with or without prednisone in patients with mCSPC or mCRPC&#xD;
      (Part 3).&#xD;
&#xD;
      The study will consist of a 45-day screening period followed by a 12-week treatment period&#xD;
      with one of the three combination treatments (Parts 1, 2, or 3). All participants are&#xD;
      required to have been treated with standard-of-care leuprolide acetate or a GnRH receptor&#xD;
      antagonist (such as degarelix) in combination with either abiraterone plus prednisone for a&#xD;
      minimum of 12 weeks prior to baseline (Day 1) (Part 1), apalutamide for a minimum of 6 weeks&#xD;
      prior to baseline (Day1) (Part 2), or docetaxel for a minimum of one treatment cycle (Part&#xD;
      3). Participants will be transitioned from standard-of-care leuprolide acetate or the GnRH&#xD;
      receptor antagonist to relugolix; with relugolix treatment initiated the day the next dose of&#xD;
      leuprolide acetate or the GnRH antagonist is scheduled for administration with the prior&#xD;
      dosing regimen of abiraterone acetate plus a corticosteroid, apalutamide, or docetaxel with&#xD;
      or without prednisone being continued.&#xD;
&#xD;
      In addition to evaluating the safety and tolerability of relugolix, the study will also&#xD;
      provide safety data as participants transition from injectable leuprolide acetate or&#xD;
      degarelix to treatment with relugolix as the androgen-deprivation component of the treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Baseline through Week 13</time_frame>
    <description>Parts 1, 2, and 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Testosterone Serum Concentrations at Baseline (Day 1), Week 5, and Week 13</measure>
    <time_frame>Baseline (Day 1), Week 5, and Week 13</time_frame>
    <description>Parts 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Proportion of Participants with Testosterone Concentrations ≥ 50 ng/dL at Baseline (Day 1), Week 5, and Week 13</measure>
    <time_frame>Baseline (Day 1), Week 5, and Week 13</time_frame>
    <description>Parts 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relugolix Trough Concentrations at Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13</measure>
    <time_frame>Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apalutamide and N-desmethyl Apalutamide Trough Concentrations at Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13</measure>
    <time_frame>Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Testosterone Serum Concentrations at Baseline (Day 1), Mid-Treatment, and Week 13</measure>
    <time_frame>Baseline (Day 1), Mid-Treatment, and Week 13</time_frame>
    <description>Part 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Proportion of Participants with Testosterone Concentrations ≥ 50 ng/dL at Baseline (Day 1), Mid-Treatment (Treatment Cycle that Most Closely Corresponds to Week 7 of the Primary Study Treatment Period), and Week 13</measure>
    <time_frame>Baseline (Day 1), Mid-Treatment (Treatment Cycle that Most Closely Corresponds to Week 7 of the Primary Study Treatment Period), and Week 13</time_frame>
    <description>Part 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relugolix Concentrations at Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel</measure>
    <time_frame>Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel</time_frame>
    <description>Part 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Docetaxel Concentrations at Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel</measure>
    <time_frame>Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel</time_frame>
    <description>Part 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Parts 1, 2, and 3</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Metastatic Castration-Resistant Prostate Cancer</condition>
  <condition>Metastatic Castration-Sensitive Prostate Cancer</condition>
  <condition>Non-Metastatic Castration-Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1: Relugolix plus Abiraterone plus a Corticosteroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive relugolix in combination with abiraterone plus a corticosteroid for 12 weeks during the study treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Relugolix plus Apalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive relugolix in combination with apalutamide for 12 weeks during the study treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Relugolix plus Docetaxel with or without Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive relugolix in combination with docetaxel with or without prednisone for 12 weeks during the study treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relugolix</intervention_name>
    <description>(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day.&#xD;
(Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day.</description>
    <arm_group_label>Part 1: Relugolix plus Abiraterone plus a Corticosteroid</arm_group_label>
    <arm_group_label>Part 2: Relugolix plus Apalutamide</arm_group_label>
    <arm_group_label>Part 3: Relugolix plus Docetaxel with or without Prednisone</arm_group_label>
    <other_name>MVT-601</other_name>
    <other_name>TAK-385</other_name>
    <other_name>T-1331285</other_name>
    <other_name>RVT-601</other_name>
    <other_name>Orgovyx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>Abiraterone acetate (1000 mg [2 x 500-mg tablets]) or fine-particle abiraterone acetate (500 mg [4 x 125-mg tablets]) will be administered orally once daily.</description>
    <arm_group_label>Part 1: Relugolix plus Abiraterone plus a Corticosteroid</arm_group_label>
    <other_name>Zytiga</other_name>
    <other_name>Yonsa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>(Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily.&#xD;
(Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required.</description>
    <arm_group_label>Part 1: Relugolix plus Abiraterone plus a Corticosteroid</arm_group_label>
    <arm_group_label>Part 3: Relugolix plus Docetaxel with or without Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.</description>
    <arm_group_label>Part 1: Relugolix plus Abiraterone plus a Corticosteroid</arm_group_label>
    <other_name>Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.</description>
    <arm_group_label>Part 2: Relugolix plus Apalutamide</arm_group_label>
    <other_name>Erleada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.</description>
    <arm_group_label>Part 3: Relugolix plus Docetaxel with or without Prednisone</arm_group_label>
    <other_name>Docefrez</other_name>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. A diagnosis of adenocarcinoma of the prostate confirmed by histologic or cytologic&#xD;
             evidence and with a documented medical history of either:&#xD;
&#xD;
               -  mCSPC (Parts 1, 2, and 3) defined as having at least two of three risk factors at&#xD;
                  the baseline (Day 1) visit:&#xD;
&#xD;
                    -  Total Gleason score of ≥ 6;&#xD;
&#xD;
                    -  Presence of ≥ 2 metastatic lesions on bone scan;&#xD;
&#xD;
                    -  Evidence of measurable visceral metastases with exception of hepatic&#xD;
                       metastases.&#xD;
&#xD;
               -  nmCRPC (Part 2 only) defined as disease progression despite maintaining&#xD;
                  castration levels of testosterone with androgen deprivation therapy (ADT), as&#xD;
                  evidenced by an increase in consecutive prostate-specific antigen (PSA)&#xD;
                  concentrations of ≥ 2 ng/mL (2 measurements, at least one week apart).&#xD;
&#xD;
               -  mCRPC (Parts 1 and 3) defined as disease progression despite maintaining&#xD;
                  castration levels of testosterone with ADT:&#xD;
&#xD;
                    -  An increase in PSA ≥ 25% and ≥ 2 ng/mL above the nadir, confirmed by 2&#xD;
                       measurements at least 3 weeks apart, and;&#xD;
&#xD;
                    -  The progression of pre-existing disease as evidenced either by worsening&#xD;
                       symptoms and/or enlarged metastatic lesions; and/or;&#xD;
&#xD;
                    -  The development of new metastases.&#xD;
&#xD;
          2. Currently receiving standard-of-care treatment of leuprolide acetate (3-, 4-, or&#xD;
             6-month injections [intramuscular Lupron or subcutaneous Eligard]) or a&#xD;
             gonadotropin-releasing hormone (GnRH) receptor antagonist (such as degarelix) in&#xD;
             combination with:&#xD;
&#xD;
               -  Part 1: abiraterone acetate 1000 mg or fine-particle abiraterone acetate 500 mg&#xD;
                  once daily plus prednisone 5 mg once daily for participants with mCSPC or twice&#xD;
                  daily for participants with mCRPC or methylprednisolone 4 mg once daily and in&#xD;
                  whom abiraterone has been well tolerated (that is, without evidence of&#xD;
                  hepatotoxicity requiring dose adjustment for abiraterone) for a minimum of 12&#xD;
                  weeks prior to initiation of the study treatment period.&#xD;
&#xD;
               -  Part 2: apalutamide 240 mg once daily and in whom apalutamide has been well&#xD;
                  tolerated (that is, without a fracture, fall, or seizure episode or need to dose&#xD;
                  adjust due to any adverse events) for a minimum of 6 weeks prior to initiation of&#xD;
                  the study treatment period.&#xD;
&#xD;
               -  Part 3: docetaxel 75 mg/m2 and in whom docetaxel has been well tolerated (that&#xD;
                  is, no evidence of hypersensitivity reaction, febrile neutropenia or neutrophils&#xD;
                  &lt; 500 cells/mm3 for more than 1 week, severe or cumulative cutaneous reactions,&#xD;
                  or moderate neurosensory signs and/or symptoms despite dose reduction) for a&#xD;
                  minimum of 1 previous treatment cycle.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Received treatment with a GnRH analog or GnRH receptor antagonist with either&#xD;
             abiraterone acetate plus a corticosteroid (Part 1) or apalutamide (Part 2) in mCSPC&#xD;
             participants (Parts 1 and 2) or nmCRPC (Part 2) for a total duration &gt; 24 months or in&#xD;
             mCRPC participants (Part 1) for a total duration &gt; 6 months.&#xD;
&#xD;
          2. Abnormal clinical laboratory test value(s) suggestive of clinically unstable&#xD;
             underlying disease or a clinical laboratory test value(s) at the screening visit or&#xD;
             prior to the baseline (Day 1) visit including:&#xD;
&#xD;
               -  (Part 1 only) Serum alanine aminotransferase and/or aspartate aminotransferase &gt;&#xD;
                  upper limit of normal (ULN) (confirmed twice during screening at least 14 days&#xD;
                  apart);&#xD;
&#xD;
               -  (Part 3 only) Serum alanine aminotransferase and/or aspartate aminotransferase &gt;&#xD;
                  1.5 times ULN concurrently with an alkaline phosphatase &gt; 2.5 times ULN;&#xD;
&#xD;
               -  (Part 1 only) Total bilirubin &gt; ULN (unless values are consistent with Gilbert's&#xD;
                  syndrome for which the total bilirubin cannot exceed &gt; 3 times ULN);&#xD;
&#xD;
               -  (Part 3 only) Total bilirubin &gt; ULN&#xD;
&#xD;
               -  (Part 1 only) Potassium &lt; 3.5 milliequivalents/liter;&#xD;
&#xD;
               -  Serum creatinine &gt; 2.0 mg/dL;&#xD;
&#xD;
               -  Platelets &lt; 100 × 10^3/microliter (μL);&#xD;
&#xD;
               -  Hemoglobin &lt; 10.0 grams/dL;&#xD;
&#xD;
               -  Leukocytes &lt; 3 × 10^3/μL;&#xD;
&#xD;
               -  Absolute neutrophil count &lt; 1.5 × 10^3/μL;&#xD;
&#xD;
               -  Hemoglobin A1c &gt; 8%.&#xD;
&#xD;
          3. A medical history within 6 months prior to the screening visit of the following&#xD;
             (myocardial infarction; unstable angina; unstable symptomatic ischemic heart disease;&#xD;
             New York Heart Association class III or IV heart failure; thromboembolic event[s]),&#xD;
             any other significant cardiac conditions, stroke (Part 2 only), transient ischemic&#xD;
             attack (Part 2 only), or medical history of seizures (Part 2 only).&#xD;
&#xD;
          4. An abnormal electrocardiogram finding&#xD;
&#xD;
          5. Uncontrolled hypertension&#xD;
&#xD;
          6. Hypotension&#xD;
&#xD;
          7. Bradycardia&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myovant Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Myovant Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials at Myovant</last_name>
    <phone>650-278-8743</phone>
    <email>ClinicalTrials@Myovant.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Urological Associates of Southern Arizona, P.C.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Urology, LLP d/b/a: MidLantic Urology</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keystone Urology Specialists</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mCRPC</keyword>
  <keyword>mCSPC</keyword>
  <keyword>Relugolix</keyword>
  <keyword>Abiraterone</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Leuprolide acetate</keyword>
  <keyword>nmCRPC</keyword>
  <keyword>Apalutamide</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Degarelix</keyword>
  <keyword>Methylprednisolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Relugolix</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

